These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 32956756

  • 41. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG.
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [Abstract] [Full Text] [Related]

  • 42. Mepolizumab incompletely suppresses clinical flares in a pilot study of episodic angioedema with eosinophilia.
    Khoury P, Makiya MA, Rahim R, Bowman A, Espinoza D, Schiffenbauer A, Koch M, Anderson C, Constantine G, Maric I, Sun X, Pittaluga S, Brown T, Ware JM, Wetzler L, Fay MP, Klion AD.
    J Allergy Clin Immunol; 2024 Mar; 153(3):821-830.e6. PubMed ID: 37951310
    [Abstract] [Full Text] [Related]

  • 43. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, Llanos JP, Kwon N.
    Respir Med; 2019 Mar; 154():69-75. PubMed ID: 31220806
    [Abstract] [Full Text] [Related]

  • 44. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
    Chen MM, Roufosse F, Wang SA, Verstovsek S, Durrani SR, Rothenberg ME, Pongdee T, Butterfield J, Lax T, Wechsler ME, Stein ML, Ogbogu PU, Kahwash BM, Mathur SK, Simon D, Akuthota P, Holland N, Wetzler L, Ware JM, Guo C, Fay MP, Khoury P, Klion AD, Bochner BS.
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
    [Abstract] [Full Text] [Related]

  • 45. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M.
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [Abstract] [Full Text] [Related]

  • 46. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
    FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M.
    Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
    [Abstract] [Full Text] [Related]

  • 47. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M, Aleman Paramo F, Kjarsgaard M, Salter B, Nair G, LaVigne N, Radford K, Sehmi R, Nair P.
    Am J Respir Crit Care Med; 2018 Jan 01; 197(1):38-46. PubMed ID: 28915080
    [Abstract] [Full Text] [Related]

  • 48. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, SIRIUS Investigators.
    N Engl J Med; 2014 Sep 25; 371(13):1189-97. PubMed ID: 25199060
    [Abstract] [Full Text] [Related]

  • 49. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M, Galkin D, Azmi J, Mouneimne D, Price RG, Liu MC.
    Allergy; 2019 Sep 25; 74(9):1716-1726. PubMed ID: 31049972
    [Abstract] [Full Text] [Related]

  • 50. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J.
    Trials; 2020 Oct 28; 21(1):897. PubMed ID: 33115543
    [Abstract] [Full Text] [Related]

  • 51. Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance.
    Caminati M, Maule M, Benoni R, Micheletto C, Tecchio C, Vaia R, De Franceschi L, Guarnieri G, Vianello A, Senna G.
    Orphanet J Rare Dis; 2023 Sep 26; 18(1):302. PubMed ID: 37752586
    [Abstract] [Full Text] [Related]

  • 52. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P, McCormack K, Malka-Rais J, Spahn JD.
    J Allergy Clin Immunol Pract; 2019 Sep 26; 7(8):2689-2696.e2. PubMed ID: 31201938
    [Abstract] [Full Text] [Related]

  • 53. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG.
    Lancet Respir Med; 2014 Nov 26; 2(11):879-890. PubMed ID: 25306557
    [Abstract] [Full Text] [Related]

  • 54. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG, ANDHI study investigators.
    Lancet Respir Med; 2021 Mar 26; 9(3):260-274. PubMed ID: 33357499
    [Abstract] [Full Text] [Related]

  • 55. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, BISE Study Investigators.
    Lancet Respir Med; 2017 Jul 26; 5(7):568-576. PubMed ID: 28545978
    [Abstract] [Full Text] [Related]

  • 56. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB.
    J Allergy Clin Immunol; 2019 Jan 26; 143(1):190-200.e20. PubMed ID: 30205189
    [Abstract] [Full Text] [Related]

  • 57. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators.
    Lancet; 2016 Oct 29; 388(10056):2128-2141. PubMed ID: 27609406
    [Abstract] [Full Text] [Related]

  • 58. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
    Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, Yancey SW, Steinfeld J.
    J Allergy Clin Immunol; 2019 Nov 29; 144(5):1336-1342.e7. PubMed ID: 31425781
    [Abstract] [Full Text] [Related]

  • 59. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
    Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintás-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE.
    Clin Cancer Res; 2009 Jan 01; 15(1):368-73. PubMed ID: 19118067
    [Abstract] [Full Text] [Related]

  • 60. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
    Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU.
    Gut; 2010 Jan 01; 59(1):21-30. PubMed ID: 19828470
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.